A Case of Interstitial Lung Disease Probably Related to Rituximab Treatment

A 44-year-old male developed interstitial lung disease (ILD) during treatment with rituximab (375 mg/m(2) weekly intravenous × 4 weeks) for the management of immune thrombocytopenia (ITP). After 1 month of treatment he developed dyspnea, fever (38.9 °C), an increase of C-reactive protein (CRP) and w...

Descripción completa

Detalles Bibliográficos
Autores principales: Calderazzo, Massimo, Rende, Pierandrea, Gambardella, Paolo, De Sarro, Giovambattista, Gallelli, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005575/
https://www.ncbi.nlm.nih.gov/pubmed/27747720
http://dx.doi.org/10.1007/s40800-015-0010-8
Descripción
Sumario:A 44-year-old male developed interstitial lung disease (ILD) during treatment with rituximab (375 mg/m(2) weekly intravenous × 4 weeks) for the management of immune thrombocytopenia (ITP). After 1 month of treatment he developed dyspnea, fever (38.9 °C), an increase of C-reactive protein (CRP) and white blood cells with hypoxemia, and decreased platelets. Chest X-ray and high-resolution computed tomography revealed diffuse bilateral lung infiltrates. He was diagnosed with severe ILD; rituximab was discontinued, and treatment with fluticasone combined with salmeterol, methylprednisolone, and omeprazole was started, with an improvement of symptoms over 15 days with normalization in CRP at 30 days. A Naranjo assessment score of 6 was obtained, indicating a probable relationship between the patient’s symptoms and the suspect drug. In conclusion, in ITP patients treated with rituximab, we suggest evaluating pulmonary endpoints through pharmaco-epidemiological observational studies.

Ejemplares similares